ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
April 2026
Nuclear Technology
February 2026
Fusion Science and Technology
Latest News
2025 annual assessments out for U.S. reactors
The Nuclear Regulatory Commission has released its 2025 annual performance assessments of the country’s 95 operating commercial nuclear reactors. And of the 95 reactors, all but five earned the highest marks.
Nuclear power plant assessments can fall under one of five categories: Licensee Response, Regulatory Response, Degraded Cornerstone, Degraded Performance, and Unacceptable Performance. Ninety reactors fell under Licensee Response, the highest performance category in safety and security. Plants that achieve this level of performance are subject to a Reactor Oversight Process (ROP) baseline inspection.
William A. Neuman, James L. Jones
Nuclear Technology | Volume 92 | Number 1 | October 1990 | Pages 77-92
Technical Paper | Development of Nuclear Gas Cleaning and Filtering Techniques / Fission Reactor | doi.org/10.13182/NT90-A34488
Articles are hosted by Taylor and Francis Online.
A conceptual design of a passively safe reactor facility for boron neutron capture therapy is presented. The facility configuration and its neutronic, thermalhydraulic, and safety issues are addressed in order to demonstrate the deployability of reactor technology for routine patient treatments and advanced research and dosimetry. The reactor has a power level of <10 MW(thermal) and is based on low-enriched UZrH fuel. The reactor facility generates a clean epithermal neutron beam capable of treating deep-seated brain tumors (∼70 mm) in <10 min. The incident fast neutron and gamma-ray contaminants in the beam are 1.8 and 0.4 Gy, respectively, for a 20-Gy therapeutic dose to a deep-seated tumor. With an expected operation schedule of ∼2000 treatment periods per year, the reactor core lifetime is equal to the 30-yr facility lifetime and no refueling is necessary. Five beam ports are available for simultaneous patient treatments allowing between 2000 and 10000 treatments per year with expansion capabilities of at least threefold for 24 h/day operation. The cost per patient treatment is small, about $1000, making the therapy very affordable. The reactor system design includes several passive safety features that allow the reactor to respond in a safe and benign manner in the event of off-normal transients. The response for various instantaneous reactivity insertions is assessed. Results show the reactor can passively respond to a reactivity insertion of 2 $ such that the maximum temperature limits of the fuel are not exceeded.